Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Apr

01

UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting

Read More Share:linkedin| twitter| email

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Read More Share:linkedin| twitter| email

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Read More Share:linkedin| twitter| email

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Read More Share:linkedin| twitter| email

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More Share:linkedin| twitter| email

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Read More Share:linkedin| twitter| email

Jan

19

UCB to acquire Zogenix

Read More Share:linkedin| twitter| email

Jan

18

Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Read More Share:linkedin| twitter| email

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Read More Share:linkedin| twitter| email

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)